Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down72.000 -2.100 (-2.834%)
Research Report

30/03/2021 17:02

{I-bank focus}Macquarie lowers JD Health (06618) to HK$124

[ET Net News Agency, 30 March 2021] Macquarie Research lowered its target price for JD
Health (JDH) (06618) to HK$124 from HK$193 and maintained its "outperform" rating.
The research house said JDH reported weaker-than-expected 2H 2020 revenue growth.
Macquarie liked that drug sales reached 50% of total sales, growing faster than any other
category in 2H. Within drug sales, prescription drugs accounted for 50%, while OTC drugs
accounted for the rest.
It thinks the drug sales could yield more recurring purchases from chronic disease
patients and give JDH more bargaining power over suppliers to enjoy a higher terminal
margin than other e-commerce categories.
Macquarie cut its FY2021/22 EPS estimates by 12%/5%. (KL)

Remark: Real time quote last updated: 27/10/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.